APA TV x Psychiatric News - How GLP-1 Agonists might Treat Alcohol and Substance Use Disorders

Glucagon Like Peptide-1, or GLP-1, receptor agonists are FDA-approved for treating type 2 diabetes and obesity but have shown potential therapeutic effect for neuropsychiatric disorders including substance use disorders (SUDs). With the challenges of the opoid epidemic ongoing this could provide a meaningful new option to clinicians if the research pans out. To walk us through the science, and the where we are in terms of the research landscape, APA TV is joined by Nora Volkow, M.D., Director of the National Institute on Drug Abuse (NIDA).APA TV x Psychiatric News - How GLP-1 Agonists might Treat Alcohol and Substance Use Disorders

Скачать видео